Aayush Wellness Launches Lung Care Tablets Targeting ₹18,913 Crore Respiratory Market

Market snapshot: Aayush Wellness Limited has expanded its preventive healthcare portfolio by launching its new Lung Care Tablets on August 29, 2026. This strategically targets the rapidly growing Indian respiratory healthcare segment, which is valued at nearly ₹18,913 crore. The product formulation is specifically designed to address condition-support needs for individuals affected by air pollution, smoking, and environmental stress.

Data Snapshot

• The target respiratory healthcare segment in India reached a size of ₹18,912.64 crore in 2025, showing a 10% YoY growth trend.
• For the first quarter ended June 30, 2026, Aayush Wellness registered total sales revenue of ₹33.11 crore, showing a 46.31% growth YoY.
• Consolidated Net Profit (PAT) for Q1 FY27 stood at ₹1.42 crore, expanding by 22.41% YoY from ₹1.16 crore.

What's Changed

• Revenue expanded 46.31% YoY to ₹33.11 crore in Q1 FY27, compared to ₹22.63 crore in Q1 FY26.
• Net profit climbed 22.41% YoY to ₹1.42 crore from ₹1.16 crore, driven by high-margin product launches.
• Operating profit margin improved to 2.36% from 2.25% in the same quarter of the previous year.

Key Takeaways

• The launch of Lung Care Tablets reflects the company's focus on condition-specific, high-growth OTC nutraceutical segments.
• By addressing environmental risks such as smoking and air pollution, Aayush Wellness aims to tap a sizeable, repeat-use consumer category.
• The strategic pivot from low-margin commodities trading to structured wellness offerings has successfully supported the top-line scaling.

SAHI Perspective

Aayush Wellness is executing a consistent transition from its historical food and herbs trading model toward a higher-margin consumer wellness platform. Launching specialized products like Lung Care and Liver Care tablets addresses structural lifestyle risks. While revenue growth of 46.31% YoY in Q1 FY27 is robust, the company continues to operate with narrow operating margins of 2.36%. Sustained gross margin improvements and lower marketing customer acquisition costs will be crucial for the company to support its current valuations as it scales.

Market Implications

The ongoing expansion of condition-support portfolios underscores the structural trend of preventive healthcare and premiumization in India’s $18 billion nutraceutical industry. Consumers are increasingly seeking active condition-support supplements to offset environmental hazards, encouraging wellness firms to build competitive product portfolios that stand out in highly fragmented digital and retail channels.

Trading Signals

Market Bias: Bullish

Supported by a 46.31% YoY revenue growth to ₹33.11 crore and a continuous pivot to higher-value OTC healthcare segments, the company maintains strong top-line momentum. Operational margin expansion will serve as the primary catalyst going forward.

Overweight: Nutraceuticals & Dietary Supplements, OTC Pharmaceuticals, Preventive Wellness

Underweight: Commodity Food Trading

Trigger Factors:

• Consistent improvement in operating profit margins above 5%
• Successful product adoption and distribution scaling in the multi-channel market
• Quarterly net profit margins exceeding 4.5%

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian respiratory healthcare segment remains a key pillar of the broader OTC market, recording ₹18,912.64 crore in 2025. This structural growth is supported by rising industrial and air pollution across major metropolitan areas, making natural lung detoxification and daily condition-specific support highly relevant and repetitive consumer behaviors.

Key Risks to Watch

• Intense brand competition in the OTC wellness and dietary supplement marketplace.
• High marketing and customer acquisition spends potentially limiting near-term operating margin expansions.
• Regulatory scrutiny regarding claims made on herbal and nutraceutical formulations.

Recent Developments

In August 2026, Aayush Wellness announced Q1 FY27 consolidated net profits rising 22.41% to ₹1.42 crore on a 46.31% revenue surge. Prior to this, the firm launched its advanced formulation 'Liver Detox Tablets' in April 2026. In mid-2025, the company established its first healthcare center featuring diagnostic smart kiosks (Health ATMs) in Virar, Maharashtra.

Closing Insight

Aayush Wellness' continuous entry into premium product lines represents a calculated effort to scale its consumer brand. If the company can successfully scale distribution channels and convert top-line growth into higher operating margins, it will establish a solid foundation for sustainable long-term valuation.

High Performance Trading with SAHI.